Join
Live feed
·
PRReleasevia Quantisnow
Mind Medicine (MindMed) Inc. logo

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

ByQuantisnow·Wall Street's wire, on your screen.
MNMD· Mind Medicine (MindMed) Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNMD (Mind Medicine (MindMed) Inc.) and more on Quantisnow.